Education
About Us
Working with TipRanks
Follow Us
FibroBiologics, Inc. (FBLG)
NASDAQ:FBLG
FBLG Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.76 - $13.59
Previous CloseN/A
Volume56.64K
Average Volume (3M)170.46K
Market Cap
$32.08M
Enterprise Value$64.60M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.59
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding37,735,300
10 Day Avg. Volume183,250
30 Day Avg. Volume170,463
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.70
P/FCF Ratio0.00
Enterprise Value/Market Cap2.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-147.81
Enterprise Value/Ebitda-3.75
Forecast
1Y Price Target
$12.00Price Target Upside1311.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
FibroBiologics, Inc. News
See All FBLG News
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe company has highlighted anticipated initiation of the Australian Phase 1/2 trial evaluating CYWC628 in DFU, while trial completion is expected by year-end, coinciding with awaited early results in DFU.
Market OpportunityChronic wound care represents a sizable market with $28B in healthcare spending, providing a significant opportunity for FibroBiologics.
Therapeutic PotentialFibroblast therapies offer a differentiated therapeutic benefit, addressing unmet needs in connective tissue formation and wound healing.
Bears Say
Financial PerformanceFibrobiologics reported 3Q24 results with an operating loss of ($3.4M) and cash of $7.8M.
Funding ConcernsThe company is expected to be funded into mid-2025.
---
Ownership Overview
16.25% Insiders
4.37% Mutual Funds
2.23% Other Institutional Investors
70.45% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
FBLG FAQ
What was FibroBiologics, Inc.’s price range in the past 12 months?
FibroBiologics, Inc. lowest stock price was $0.76 and its highest was $13.59 in the past 12 months.
What is FibroBiologics, Inc.’s market cap?
FibroBiologics, Inc.’s market cap is $32.08M.
When is FibroBiologics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were FibroBiologics, Inc.’s earnings last quarter?
FibroBiologics, Inc. released its earnings results on Nov 12, 2024. The company reported -$0.01 earnings per share for the quarter, beating the consensus estimate of -$0.072 by $0.062.
Is FibroBiologics, Inc. overvalued?
According to Wall Street analysts FibroBiologics, Inc.’s price is currently Undervalued.
Does FibroBiologics, Inc. pay dividends?
FibroBiologics, Inc. does not currently pay dividends.
What is FibroBiologics, Inc.’s EPS estimate?
FibroBiologics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does FibroBiologics, Inc. have?
FibroBiologics, Inc. has 37,735,300 shares outstanding.
What happened to FibroBiologics, Inc.’s price movement after its last earnings report?
FibroBiologics, Inc. reported an EPS of -$0.01 in its last earnings report, beating expectations of -$0.072. Following the earnings report the stock price went down -4.444%.
Which hedge fund is a major shareholder of FibroBiologics, Inc.?
Among the largest hedge funds holding FibroBiologics, Inc.’s share is Fund Evaluation Group, LLC. It holds FibroBiologics, Inc.’s shares valued at 0.
---
FibroBiologics, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (1311.76% Upside)
$12.00 (1311.76% Upside)
Blogger Sentiment
Bullish
FBLG Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-92.98%
12-Months-Change
Fundamentals
Return on Equity
-559.73%
Trailing 12-Months
Asset Growth
87.14%
Trailing 12-Months
Company Description
FibroBiologics, Inc.
FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
---
FBLG Stock 12 Month Forecast
Average Price Target
$12.00
▲(1311.76% Upside)
Technical Analysis
Fate Therapeutics
―
Karyopharm Therapeutics
―
FibroGen
―
Blueprint Medicines
―
Arcus Biosciences
―
Best Analysts Covering FBLG
1 Year
1 Year Success Rate
0/4 ratings generated profit
1 Year Average Return
-48.00%
reiterated a buy rating 12 days ago
Copying Matthew Caufield's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -48.00% per trade.
---